Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174264 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
A Phase 1 study of Malignant Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01174264 is a Phase 1 study of Malignant Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 63 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01174264, a Phase 1 study of Malignant Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized clinical trial studies the effect of food on the pharmacokinetics of vismodegib. Studying the effects of meals on the absorption of vismodegib may help doctors prescribe correct doses and label the drug accurately.
Conditions Studied
Interventions
- DRUG Vismodegib
- OTHER Pharmacological Study
Study Locations (1)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174264
The ClinicalTrials.gov registry entry for NCT01174264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (88% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT01174264 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01174264 about?
NCT01174264 is a clinical study titled "Evaluation of Food Effect on Pharmacokinetics of Vismodegib". This randomized clinical trial studies the effect of food on the pharmacokinetics of vismodegib. Studying the effects of meals on the absorption of vismodegib may help doctors prescribe correct doses and label the drug accurately.
What is the current status of trial NCT01174264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2009-10. Estimated completion is 2014-12.
What conditions does trial NCT01174264 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT01174264?
The interventions under investigation include: Vismodegib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01174264?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01174264 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
RECRUITING · Phase 1
-
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
RECRUITING · Phase 1
-
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.